Tags: Drug.
Tremelimumab (formerly ticilimumab CP-675206) is a fully human IgG2 monoclonal antibody produced by Pfizer undergoing human trials for the treatment of cancer. Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However there is also an inhibitory mechanism that interrupts this destruction.